DexCom, Inc. vs Schlumberger NV — how do they compare? DexCom, Inc. trades at $89.04 (market cap $33.79B), while Schlumberger NV trades at $52.87 (market cap $79.67B). The key difference: Schlumberger NV is far larger — about 2.4× DexCom, Inc.'s market cap, and Schlumberger NV pays a 2.2% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SLB | |
|---|---|---|
Market Cap | $33.79B | $79.67B |
Sector | Health | Energy |
52-Week High | $89.53 | $58.01 |
52-Week Low | $54.84 | $31.72 |
Enterprise Value | $33.24B | $88.40B |
Dividend Yield | — | 2.2% |
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
SLB trades at $53.20, up 5.28% over the past day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.55 versus $0.511 expected, driven by digital and production growth. Revenue for 2025 was $35.71 billion, with net income of $3.37 billion, though margins have compressed from prior years. The stock shows robust institutional support and positive media sentiment following upbeat results.
Outlook remains positive with a consensus price target of $63.00, implying 18% upside, supported by offshore and digital expansion. Risks include Middle East volatility and net debt concerns. The dividend yield is modest at around 1.1%, with the next payment scheduled for October 2026. Investors should weigh growth catalysts against regional and macroeconomic headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →